CITA Biomedical Appoints Steven J. Rutlen President and Chief Operating Officer
Former KPMG Executive to Assume Wide Range of Management Responsibilities
BEVERLY HILLS, Calif., Oct. 18 /PRNewswire-FirstCall/ -- CITA Biomedical, Inc. (CITA) (OTC Bulletin Board: DTOX) a growing leader in the treatment of substance dependency, today named Steven J. Rutlen as the company's president and chief operating officer (COO).
Rutlen brings over twenty years of operational and strategic planning experience to CITA. He recently retired from KPMG LLP, where he was western area Partner-in-Charge of KPMG's $120 million International Executive Services (IES) practice.
Mr. Rutlen also served as senior member of the firm's Executive Committee for the IES practice which set the strategic objectives and developed the operations plan to grow market share. He has experience in the addiction and healthcare field. During his tenure with KPMG he served as a Healthcare Practice consultant to healthcare providers including hospital and physicians groups as well as medical insurance companies.
"I am delighted that Steve has chosen to join CITA to lead our operations. As we refine our strategy and organization to meet the demands of our major market expansion as well as put us in position for long term growth, his experience will be invaluable," Joseph Dunn, chairman and CEO of CITA Biomedical. "Steve's expertise will help accelerate CITA's DNA for Addictions roll-out and market expansion across the U.S. and Canada."
"I am very pleased to be joining the CITA management team at this time," said Mr. Rutlen. "With an exciting new treatment family, DNA for Addictions and the expanded market opportunity it provides, CITA has a unique opportunity to capture a leading share of the addiction treatment market."
In his role as president and chief operating officer at CITA Biomedical, Mr. Rutlen will be responsible for day-to-day management of the company's core operations. His appointment is effective immediately.
About CITA Biomedical, Inc.
CITA Biomedical, Inc., headquartered in Beverly Hills, Calif., focuses on the innovative treatment of addiction. The company holds the U.S. patent for its successful UROD (Ultra Rapid Opiate Detoxification) treatment method. UROD is the only clinically tested and effective treatment method to rapidly detoxify individuals addicted to opiate-based drugs, including heroin within four to six hours with few, if any, withdrawal symptoms. The company has a new family of revolutionary treatments, Detoxification and NeuroAdaptation (DNA) for Addictions. The first treatments from this family treat alcohol, cocaine, crack, and poly-drug addictions. To date, CITA has grown its business through internal expansion and now seeks compatible, leading, and complementing technologies and acquisitions to enhance its corporate portfolio. CITA Biomedical, Inc. has two operating divisions CITA Americas, Inc., and AltTPro, Inc. For more information, please visit www.citabio.com
UROD is a registered trademark of CITA Biomedical, Inc.
For further information, please contact investors, Judy Ryon of CITA Biomedical, Inc., +1-310-550-4971, email@example.com; or Treatment Information, +1-888-400-2482, www.citatreatment.com
SOURCE CITA Biomedical, Inc.
CONTACT: Judy Ryon of CITA Biomedical, Inc., +1-310-550-4971,
firstname.lastname@example.org; or Treatment Information, +1-888-400-2482/
PRN Photo Desk, 888-776-6555 or 212-782-2840/
Web site: http://www.citatreatment.com
Web site: http://www.citabio.com